C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY.
Fireside Chat Details:
Date: Wednesday, February 11, 2026
Time: 11:30 AM ET
A live webcast will be available on the Investors section of the company’s website at . An archived replay of the webcast will be available for approximately 90 days following the event.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit .
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
